Connect with us

Hi, what are you looking for?


Peso may climb vs the dollar on BSP easing, vaccine news

THE PESO may strengthen against the dollar this week after the central bank cut borrowing costs anew and on continued progress in trials for coronavirus disease 2019 (COVID-19) vaccine candidates.

The local unit closed at P48.23 on Friday, rising by 8.5 centavos from its P48.315 finish on Thursday, data from the Bankers Association of the Philippines showed.

Week on week, however, the peso declined by two centavos from its P48.21 finish on Nov. 13.

Rizal Commercial Banking Corp. Chief Economist Michael L. Ricafort said the peso strengthened after the Bangko Sentral ng Pilipinas (BSP) slashed key interest rates to new record lows.

“This will help boost economic recovery prospects in terms of further reducing borrowing costs, spur greater demand for loans that boost investments, jobs, economic opportunities, and more gains in the local financial markets,” Mr. Ricafort said.

The BSP Monetary Board on Thursday unexpectedly slashed benchmark interest rates by another 25 basis points to accelerate economic recovery amid the surge of COVID-19 cases in certain countries.

This brought down the rates on the BSP’s overnight reverse repurchase, lending and deposit facilities to new record lows of 2%, 2.5%, and 1.5%, respectively.

For this week, Mr. Ricafort said the peso may continue rising as the government disburses more funds out of the P165.5 billion programmed under Republic Act 11494 or the Bayanihan to Recover as One Act.

“The peso could be stronger with faster utilization of the Bayanihan II Law funds that could lead to faster economic recovery,” he said in an e-mail.

Meanwhile, a trader said the peso may also strengthen as drug companies advance in their development of COVID-19 vaccines.

Pharmaceutical companies and research centers around the world are working on potential COVID-19 vaccines, with large global trials of several of the candidates involving tens of thousands of participants underway, Reuters reported.

The US Food and Drug Administration’s outside advisers will meet on Dec. 10 to discuss whether to authorize the COVID-19 vaccine developed by Pfizer, Inc. and German partner BioNTech for emergency use, the agency said on Friday.

Meanwhile, AstraZeneca started late-stage trials on Saturday of an experimental long-acting monoclonal antibody combination drug it hopes could be used as a so-called prophylactic to prevent COVID-19 infection in at-risk people for up to 12 months.

The dollar on Friday rose against major currencies such as the euro and yen, with traders consolidating positions amid competing forces that pull the currency in different directions: the surge in virus cases, on the one hand, and positive vaccine news, on the other.

For this week, Mr. Ricafort sees the peso moving from P48.10 to P48.35 versus the dollar, while the trader expects it to range from P48.15 to P48.30. — KKTJ with Reuters

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!



WASHINGTON D.C. — The United States is seeking to form a coalition of countries to drive negotiations on a global plastic pollution treaty, weeks...


By Diego Gabriel C. Robles  THE WORLD BANK (WB) upgraded its growth forecast for the Philippines for this year and 2023, citing an “accommodative”...


THE PHILIPPINE auto industry’s sales recovery will likely be derailed if a measure reimposing excise taxes on pickup trucks is signed into law, according...


THE BANGKO SENTRAL ng Pilipinas (BSP) may deliver a second off-cycle rate hike in early November when the US Federal Reserve is expected to...


THE ASIAN Development Bank (ADB) is planning to allocate at least $14 billion for a program aimed at easing a food crisis in the...


With the reversal of the 1.25% rise in National Insurance Contributions happening on the 6th of November, employers across the nation have an opportunity...

You May Also Like


Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...


The minute that any question pops into your head, you can simply ask Google. No longer do we have to pour over books and...


Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered throughout...


Ivermectin, an existing drug against parasites including head lice, has had a checkered history when it comes to treating COVID-19. The bulk of studies...

Disclaimer:, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.